Estimate Recalculated May 19, 2025 08:11PM EST
Deerfield Mgmt III, L.P. does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Fractyl Health, Inc., RHYTHM PHARMACEUTICALS, INC., XERIS PHARMACEUTICALS INC, REGENXBIO Inc., Editas Medicine, Inc., Shockwave Medical, Inc., AERIE PHARMACEUTICALS INC, ARVINAS INC., Neos Therapeutics, Inc., Avalanche Biotechnologies, Inc., GRAYBUG VISION, INC., Acutus Medical, Inc., Larimar Therapeutics, Inc., Syros Pharmaceuticals, Inc., CytomX Therapeutics, Inc., PROTEON THERAPEUTICS INC, AveXis, Inc., SteadyMed Ltd., aTYR PHARMA INC, LUMOS PHARMA, INC., ALIMERA SCIENCES INC, Homology Medicines, Inc., Oncorus, Inc., Audentes Therapeutics, Inc., and ARS Pharmaceuticals, Inc..
Deerfield Mgmt III, L.P.'s CIK is 0001610540
No data available
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!